Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Mineralys Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Mineralys Therapeutics, Inc.

MLYS

Mineralys Therapeutics, Inc.

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing medicines targeting diseases driven by dysregulated aldosterone. Its lead product, lorundrostat, is a highly selective oral aldosterone synthase inhibitor aimed at treating hypertension, chronic kidney disease, and obstructive sleep apnea. The company focuses on innovative therapies for cardiorenal conditions, leveraging proprietary compounds and strategic licensing to address unmet medical needs in cardiovascular and renal health.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Mineralys Therapeutics, Inc.

1
1
Mineralys Therapeutics, Inc. Mineralys Therapeutics Reports Q1 2026 Financial Results with $39.3M Net Loss

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Mineralys Therapeutics, Inc. Mineralys Therapeutics Faces Challenges Despite Positive Clinical Trial Results for Lorundrostat

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Mineralys Therapeutics, Inc. Mineralys Therapeutics Reports Decreased Net Loss and Increased Cash Position in Latest 10-Q Filing

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Mineralys Therapeutics, Inc. Mineralys Therapeutics Reports $43.3 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Mineralys Therapeutics, Inc. Mineralys Therapeutics Reports $42.2 Million Net Loss and Advances Clinical Trials for Lorundrostat

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Mineralys Therapeutics, Inc. Mineralys Therapeutics Reports $177.8 Million Net Loss for 2024, Increased R&D Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Mineralys Therapeutics, Inc. Mineralys Therapeutics Reports Increased Cash Reserves, Rising Operating Expenses, and Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments